Company

Company

The Aenova Group is a leading global contract manufacturer and development services provider for the pharmaceutical and healthcare industry. Our services include end-to-end manufacturing and development of all dosage forms and potency levels (ranging from nutraceuticals to high-potents) out of 14 sites in Europe and the US.

With our comprehensive know-how, many years of experience, well-trained staff of 4,000 employees, innovative technologies and highest quality standards we are a reliable, long-term partner to pharmaceutical and consumer health care customers around the world, both in the human and veterinary healthcare market.

Milestones to a globally leading CDMO

back
2008

2008

Foundation of Aenova Group

Swisscaps Dragenopharm
2008
2024

2024

Aenova wins 'Highest
Innovative Strength'
award

Siegel Innovationskraft 2024 HÖ CHSTE Aenova
2024
2023

2023

Aenova further expands in capacities and innovative technologies

Chart
2023
2021

2020 - 2022

Largest investment program in differentiated technologies/ innovation in corporate history

Chart green
2021
2020

2020

  • Expansion III Tittmoning solids (SOL)
  • Gronau sterile ampoules expansion
Packaging new
2020
next
Main corporate events
Main manufacturing/services events

Aenova was created 2008, as a merger of pharmaceutical companies Dragenopharm and Swiss Caps, forming the nucleus of the group. In 2012, the Temmler Group was acquired, and at the beginning of 2014 Haupt Pharma was acquired. The majority shareholder of Aenova is Kühne Holding AG.